Search

Your search keyword '"Andrey Verbovoy"' showing total 6 results
Start Over Author "Andrey Verbovoy"
6 results on '"Andrey Verbovoy"'

1. Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial

Author

Olga Smirnova, Olga Ershova, Marina Shestakova, Boris Kvasnikov, Ekaterina Erina, Elena Isachenko, Alexander Andreev, Diana Alpenidze, Alexander Ametov, Olga Demicheva, Irina Dvoryashina, Polina Ermakova, Elena Grineva, Yuriy Khalimov, Ludmila Kvitkova, Anatoliy Kuzin, Olga Lantseva, Nina Leonova, Tatiana Lysenko, Tatiana Markova, Ashot Mkrtumyan, Nina Nosova, Natalia Osokina, Leonid Pimenov, Larisa Rogova, Ludmila Ruyatkina, Oksana Rymar, Olesya Shabelnikova, Elena Smirnova, Alexander Sobolev, Leonid Strongin, Ludmila Suplotova, Andrey Verbovoy, Anna Volkova, Alsu Zalevskaya, Olga Zanozina, Elena Zhdanova, and Larisa Zhukova

Subjects
Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Introduction Most data demonstrating the efficacy and safety of luseogliflozin (luseo) in people with type 2 diabetes mellitus (T2DM) originate from the Japanese population. This study evaluated luseo versus placebo (PCB) as add-on to metformin in a Caucasian population with inadequately controlled T2DM.Research design and methods This was a multicenter, randomized, double-blind, PCB-controlled, parallel-group study. Patients aged 18–75 years with inadequately controlled T2DM (glycated hemoglobin (HbA1c) ≥7% to ≤10% (≥53 to ≤86 mmol/mol)) despite a diet and exercise program and on a stable metformin regimen were eligible. Patients were randomized to one of three luseo groups (2.5, 5.0 and 10.0 mg) or PCB for 12 weeks (W12). The primary endpoint was change in HbA1c expressed as least-square means from baseline (W0) to W12.Results A total of 328 patients were randomized: PCB (n=83) and luseo 2.5 mg (n=80), 5.0 mg (n=86), and 10.0 mg (n=79). Mean age (±SD) was 58.5±8.8 years; 64.6% were women; body mass index was 31.5±3.4 kg/m2; and HbA1c was 8.54±0.70. At W12, mean reductions in HbA1c from W0 were −0.98%, −1.09%, −1.18%, and −0.73% in the luseo 2.5, 5.0 and 10.0 mg, and PCB groups, respectively, all of which were statistically significant. Compared with PCB, HbA1c levels were significantly decreased by 0.25% (p=0.045), 0.36% (p=0.006), and 0.45% (p=0.001) in the luseo 2.5, 5.0, and 10.0 mg groups, respectively. In all luseo dose groups, reductions in body weight were statistically significant compared with PCB. Data from the safety analysis were consistent with the known luseo safety profile.Conclusions All doses of luseo as add-on to metformin in Caucasian patients with uncontrolled T2DM demonstrated significant efficacy in decreasing HbA1c after W12 of treatment.Trial registration number ISRCTN39549850.

Published
2023
Full Text
View/download PDF

2. Association between pathogenesis of atherosclerosis and osteoporosis

Author

Andrey Verbovoy, Ekaterina Mitroshina, and Anna Pashentseva

Subjects
osteoporosis, atherosclerosis, cardiovascular disease, osteoprotegerin, vitamin d3, Physiology, QP1-981, Biochemistry, QD415-436
Abstract

Currently, the leading place in the structure of morbidity in older people takes the cardiovascular disease. It is also the leading cause of death in developed countries. The significance of osteoporosis is now also due to the high and growing prevalence of this pathology. Osteoporotic fractures are associated with a reduction in the quality of life in patients, lead to disability, require a significant investment. This pathology is ranked fourth in the structure of mortality after cardiovascular disease, oncopathology, and diabetes.Numerous studies indicate that these two diseases are associated not only with the occurrence of age, but have common pathogenetic mechanisms. The data obtained suggest that osteoporosis, calcification of the aorta and heart valves and atherosclerotic vascular disease – related pathological processes. Vascular and bone have some common morphological properties, vascular calcification and consists of the same components as the bone tissue.From the standpoint of modern medicine it is extremely important to identify specific relationships between diseases and their common pathogenetic mechanisms for development of a comprehensive and individual approach to the diagnosis, treatment and prevention.

Published
2016
Full Text
View/download PDF

3. Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy

Author

Maria Fleseriu, Andrey Verbovoy, Murray B. Gordon, Mark E. Molitch, Yulia Pokramovich, Nienke Biermasz, Alexander Dreval, Nina Leonova, Christian J. Strasburger, Sergey A. Dogadin, William H. Ludlam, Irina Bondar, Elena Isaeva, Gerald Raverot, Gilgun-Sherki Yossi, Djuro P Macut, Gary Patou, Asi Haviv, and Shlomo Melmed

Subjects
medicine.medical_specialty, Combination therapy, business.industry, Endocrinology, Diabetes and Metabolism, Octreotide, medicine.disease, Dopamine agonist, Gastroenterology, 3. Good health, law.invention, Discontinuation, Neuroendocrinology and Pituitary, Clinical Trials and Study Updates in Neuroendocrinology and Pituitary, Randomized controlled trial, law, Internal medicine, Cabergoline, Acromegaly, medicine, In patient, business, Adverse effect, AcademicSubjects/MED00250, medicine.drug
Abstract

Background: Oral octreotide capsules (OOC; MYCAPSSA®) are approved in the US for individuals with acromegaly who responded to and tolerated treatment with injectable somatostatin receptor ligands (iSRLs). Add-on cabergoline therapy has shown effectiveness in patients previously inadequately controlled with iSRLS.1 The phase 3 MPOWERED trial assessed maintenance of response with OOC compared to iSRLs. Patients receiving OOC and ineligible for randomized controlled treatment (RCT) phase were eligible for a sub-study evaluating combination therapy with cabergoline, a dopamine agonist. Methods: Patients who fail to respond to 80 mg/d OOC for ≥2 weeks during the 26-week Run-in phase, or ineligible to enter the RCT on 80 mg/d OOC, due to inadequate biochemical control (insulin-like growth factor I [IGF-I] ≥1.3 × upper limit of normal [ULN] to Results: Of 146 patients enrolled in MPOWERED, 14 entered the combination sub-study, 9 having IGF-I ≥1.3 × ULN at sub-study start. Final cabergoline doses were 1 (n=5), 2 (n=3), 3 (n=1), and 3.5 mg (n=5) with 25.4-week (SD, 14.1) mean treatment duration. Week 36 IGF-I improved in most patients (n=12; 85.7%). Of 9 patients with IGF-I ≥1.3 × ULN at sub-study start, 5 (55.6%; 95% CI, 21.2%-86.3%) exhibited IGF-I decreased to predefined responder range ( Conclusion: We have shown for the first time the benefit of an all-oral combination treatment for acromegaly and avoidance of injection-related burdens. Addition of cabergoline to OOC yielded biochemical control improvement (IGF-I reduction) in patients inadequately controlled with OOC monotherapy. As both combination and OOC monotherapy safety profiles were similar, adjunctive cabergoline may be helpful in patients with acromegaly who do not achieve adequate biochemical control on OOC alone. 1Giustina A, et al. Nat Rev Endocrinol. 2014;10(4):243-248.

Published
2021
Full Text
View/download PDF

6. The levels of resistin and other adipokines in patients with hypothyroidism

Author

Verbovaya, N. I., Kapralova, I. Yu, and Andrey Verbovoy

Subjects
endocrine system, endocrine system diseases, adiponectin, lcsh:R, fat metabolism, nutritional and metabolic diseases, lcsh:Medicine, hypothyroidism, leptin, hormones, hormone substitutes, and hormone antagonists, resistin
Abstract

AIM. To investigate the relationship of resistin, adiponectin, leptin, and hormone metabolic parameters in patients with hypothyroidism. MATERIALS AND METHODS. Ninety-three women aged 58.0 (53.0-63.0) years with hypothyroidism were examined. A control group consisted of 10 women aged 48 (47-50) years. Anthropometric characteristics, glucose and lipid metabolic parameters, and leptin, resistin, adiponectin levels were studied. RESULTS. The patients with hypothyroidism were found to have statistically significantly enhanced insulin resistance (IR) and compensatory hyperinsulinemia in the presence of android fat distribution. The found atherogenic dyslipidemia manifested itself as an increase in the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and atherogenic index and as a reduction in high-density lipoprotein cholesterol. The concentration of leptin and resistin was increased and that of adiponectin was reduced in the patients with hypothyroidism. There was a correlation of leptin and adiponectin with fat metabolic parameters. CONCLUSION. The women with hypothyroidism had enhanced IR, as well as compensatory hyperinsulinemia in the presence of android fat distribution. Hypothyroidism is accompanied by the development of atherogenic dyslipidemia. The concentration of leptin and resistin was elevated and that of adiponectin was reduced in the examinees.

Catalog

Books, media, physical & digital resources
See catalog results